Home > Boards > US Listed > Biotechs > Seattle Genetics (SGEN)

SGEN is a great $$$$$ opportunity.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
crudeoil24 Member Profile
Member Level 
Followed By 611
Posts 39,101
Boards Moderated 6
Alias Born 12/12/04
160x600 placeholder
Seattle Genetics to Present at the Cowen 40th Annual Healthcare Conference Business Wire - 2/26/2020 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/20/2020 5:34:37 PM
Five Prime Therapeutics In License Agreement with Seattle Genetics Dow Jones News - 2/19/2020 10:31:00 AM
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combina... PR Newswire (US) - 2/19/2020 8:28:00 AM
Seattle Genetics & Astellas Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combinati... Business Wire - 2/19/2020 8:12:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 1:38:19 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 12:11:05 PM
Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients wit... Business Wire - 2/13/2020 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/12/2020 5:39:52 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 2:53:27 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 11:15:05 AM
Seattle Genetics & Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combinat... Business Wire - 2/11/2020 8:00:00 AM
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combin... PR Newswire (US) - 2/10/2020 5:00:00 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/7/2020 8:46:46 AM
Annual Report (10-k) Edgar (US Regulatory) - 2/6/2020 5:19:34 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/6/2020 4:11:25 PM
Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire - 2/6/2020 4:02:00 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 2/6/2020 12:54:01 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/5/2020 6:08:55 PM
EMA Validates Seattle Genetics’ Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Met... Business Wire - 1/31/2020 8:00:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 1/28/2020 9:11:39 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 1/28/2020 9:10:31 AM
Schedule 13g Edgar (US Regulatory) - 1/27/2020 3:57:34 PM
Seattle Genetics to Host Conference Call & Webcast Discussion of Fourth Quarter & Full Year 2019 Financial Results on Februar... Business Wire - 1/21/2020 8:30:00 AM
Seattle Genetics Achieves Milestone Following European Commission Approval of Roche’s Polivy® (Polatuzumab Vedotin) Business Wire - 1/21/2020 8:00:00 AM
crudeoil24 Member Level  Friday, 11/16/18 02:52:58 PM
Re: crudeoil24 post# 243
Post # of 254 
SGEN is a great $$$$$ opportunity.

New York Yankees and Duke Basketball
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
© 2020 InvestorsHub.com, Inc.